Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01790594 · ClinicalTrials.gov registry record · Phase 2
Optimization of NULOJIX® Usage Towards Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Terminated
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT01790594 is a Phase 2 study that was terminated before completion, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 46 participants.
The verdict
NCT01790594, a Phase 2 study, was terminated before completion, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if the drug NULOJIX® (belatacept) will minimize the amount of other anti-rejection medications necessary and thereby reduce the long-term side effects caused by the other medications. The researchers also want to learn more about the safety of this treatment and long term health of transplanted pancreases and kidneys.
Interventions
- DRUG Tacrolimus
- BIOLOGICAL Belatacept
- DRUG methylprednisolone
- DRUG Mycophenolate mofetil
- BIOLOGICAL Anti-thymocyte Globulin (Rabbit)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2013-02 |
| Est. Completion | 2016-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01790594
The ClinicalTrials.gov registry entry for NCT01790594 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Tacrolimus is the first listed.
NCT01790594 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01790594 about?
NCT01790594 is a clinical study titled "Optimization of NULOJIX® Usage Towards Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation". The purpose of this study is to find out if the drug NULOJIX® (belatacept) will minimize the amount of other anti-rejection medications necessary and thereby reduce the long-term side effects caused by the other medications. The researchers also want to learn more about the safety of this treatment ...
What is the current status of trial NCT01790594?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2013-02. Estimated completion is 2016-08.
What interventions are being tested in trial NCT01790594?
The interventions under investigation include: Tacrolimus (DRUG), Belatacept (BIOLOGICAL), methylprednisolone (DRUG), Mycophenolate mofetil (DRUG), Anti-thymocyte Globulin (Rabbit) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01790594?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.